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• Provision of easily accessible palliative care 
• Access to support for patients and carers
These aims are delivered by care networks and assessed by prospective 
continuous audit of key outcome measures. 
Lung cancer in Scotland has had poor and unchanging 1outcomes 
ascribed to low and uneven access to optimal care2. The variable 
experience and suboptimal care provided for patients with lung cancer 
in Scotland was further highlighted during a national programme of 
standard setting and peer review organised by the Clinical Standards 
Board for Scotland.3 During a period spanning 2000/1 every hospital 
providing lung cancer care was assessed by submitting a self report on 
deﬁned number of service standards and subsequent external review 
which included patients and carers. 
We describe the process of reorganisation of lung cancer services 
in Scotland over the last twelve years and its effects on outcomes for 
patients with lung cancer.
In 2001, Scotland launched a comprehensive national cancer 
strategy4, which radically changed the way that all cancer services 
are planned and delivered. The beneﬁts of this reorganisation that are 
relevant to lung cancer include:
• formation of multidisciplinary disease speciﬁc networks serving a 
deﬁned population area and working across organisational boundaries 
• access to multi-disciplinary decision making
• establishment of prospective audit measuring and reporting com-
prehensive service performance against national standards based on 
evidence based guidelines (SIGN)
This national program of reform was supported by about $500 million 
of additional targeted investment providing:
• improvements in diagnostic facilities particularly increased CT scan-
ning capacity
• improved access to modern radiotherapy with replacement of old 
equipment and expansion of existing capacity and access to 3D 
conformal treatment 
• improved access to new drugs through a national programme of 
review and regional implementation
• national PET programme 
• cancer trials network that has led to 13% of all Scottish cancer 
patients participating in clinical trials. 
• appointment of additional staff
Impact of these changes is seen in comparison of lung cancer patients 
cohorts within deﬁned geographical area served by one cancer network 
(www.scan.scot.nhs.uk) and participating in prospective audit with 
>90% capture and 98% accuracy.
Comparison of treatment intent and delivery
1995, N=927 2002, N=971 2004, N=939 Chi squared
Any treatment 582 (63%) 605 (62%) 568 (60%) P=0.85
Potentially curative 131 (14%) 229 (24%) 230 (25%) P<0.001
 Palliative 451 (49%) 376 (39%) 338 (35%)
Surgery 95 (10.2%) 102 (10.5%) 91 (9.7%) P=0.88
Radiotherapy 400 (43%) 433 (45%) 378 (40%) P=0.55
Radical1 44 (4.7%) 146 (15%) 149 (16%) P<0.001
 Palliative 356 (38%) 296 (31%) 229 (24%)
Chemotherapy 151 (16%) 196 (20%) 249 (27%) 249 (27%)
 
Survival comparison
Median 1 year 2 year
1995 N=927 4.1(3.5-4.6) 23.4% (20.7-26.1) 11.4% (9.3-13.5)
2002N=971 5.1 (4.5-5.8) 28.9% (26.1-31.8) 14.8% (12.5-17.1)
Log rank p=0.0029,
In addition to the hard endpoints of treatment and survival these 
reforms have radically improved qualitative measures such as access to 
information, Clinical Nurse Specialists and symptom management.
One remaining question is why do 1 in 3 Scottish cancer patients still 
do not receive any anti-cancer therapy? It may be appropriate in elderly 
population with high levels of co-morbidity, but further prospective 
population based studies of the decision making process are required.
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Sometimes it is not easy to decide whether to treat or not in lung cancer 
patients (1). Among patients who died of lung cancer, signiﬁcant pro-
portions were found to have received chemotherapy up to the end-of-
life and to have visited ERs. Palliative care and hospice referrals were 
not conducted well during the end-of-life period (2). 
Palliative Chemotherapy:
Among patients who died of cancer, chemotherapy was used frequently 
in the last 3 months of life. The cancer’s responsiveness to chemothera-
py does not seem to inﬂuence whether dying patients receive chemo-
therapy at the end of life (3).
In our study, newly diagnosed chemo-naïve patients with advanced or 
recurrent NSCLC (n= 404) were evaluated. All patients were histologi-
cally or pathologically proven to be NSCLC, with performance status 
0 to 2. All patients received platinum-based combination chemotherapy 
as the ﬁrst-line treatment. The old age group was deﬁned as patients 
with 65 years or more of age. The average number of total regimens 
(2.31 of old age vs. 2.81 of young age, respectively; p<0.001) and 
cycles (8.78 vs. 10.69, p=0.006) per head were signiﬁcantly less in the 
old age group than in the young age group. 
Multi-center study in Korea showed that 48.7 % of cancer patients in 
the last 6 months of life, 43.9% in the last 3 months, and 30.9% in the 
last month of life received chemotherapy in Korea. The frequency of 
chemotherapy use was lower for older patients (P for trend < 0.001). In 
those older than 65 years, there was no difference between women and 
men in the proportion that received chemotherapy. For patients < 65 
years of age, however, a larger proportion of women than men received 
chemotherapy, and chemotherapy use was signiﬁcantly less frequent for 
patients with refractory disease than for those with responsive disease. 
This difference, however, was lower for patients older than 65 years of 
age. Patients dying at a relatively small hospital without a hospice inpa-
tient unit were signiﬁcantly more likely to receive chemotherapy than 
patients at a larger, hospice-containing hospital, as were patients with 
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Medicaid relative to patients with national health Insurance. Despite 
the fact that most cancer patients are resistant to chemotherapy at the 
end of life, it was administered often to all age groups. The frequency 
of chemotherapy administration differed between men and women and 
between patients with and without chemo-responsive disease, and the 
differences varied with age. 
End-of-Life Care:
Seoul National University Hospital data showed that median dura-
tion of chemotherapy was 6.02 months (mo) compared to 8.67 mo for 
median overall survival in cancer patients. The median period between 
last chemotherapy and death was 2.02 mo. Of the 298 patients, 50.3% 
received chemotherapy during the last two months of life. Furthermore, 
17 patients (5.7%) died within 2 weeks after receiving chemotherapy. 
The proportion who visited an emergency room (ER) more than once 
during the last months of life was 33.6%, and the average number of 
ER visits after a diagnosis of cancer was 1.72. Only 9.1% of patients 
were referred to a hospice center and only 11.7% of patients agreed 
with written DNR. 
In our study, 80 patients who admitted to ICU were evaluated. 
51(63.8%) patients died in ICU, and among 29 (36.3%) patients who 
survived their ICU stay, additional 13 (16.2%) died in general ward. 
Overall in-hospital mortality was 80% (64/80). Median survival from 
the time of intubation was 13 days for all patients (including survivors). 
Uncontrolled disease (disease progression after previous chemo-
therapy) and intubation more than three days after hospitalization were 
signiﬁcantly associated with in-hospital deaths in uni-variate and multi-
variate analysis. Old age (>60yrs), leukopenia, and performance status 
were not signiﬁcant prognostic variables associated with in-hospital 
deaths. Mortality of cancer patients admitted to ICU for mechanical 
ventilation was very high. Patients with uncontrolled disease or long-
term hospitalization prior to respiratory failure are not likely to beneﬁt 
from intensive care.
Discrepancies among patients, family members, and physicians in 
terms of values:
Oh et al. showed difﬁculties in decision regarding the withholding of 
treatment from patients with terminal malignancies (4). 100% of the 
families and 87% of the patients has some knowledge of cancer, but 
only 69% of the families and 37% of the patients clearly understood the 
stage of cancer. The use of a new agent with only partial efﬁcacy (ca. 
15%) was accepted by 41% of the physicians and by 60% of the fami-
lies. The concordance rate between physicians and family members, for 
the same patient was 42%. The rankings of the acceptance of treat-
ment by physicians were, opioid analgesics (100%), antibiotics (91%), 
feeding tube (87%) and intravenous nutrition (78%). The rankings of 
the same items by family members were, opioid analgesics (92%), 
antibiotics (89%), intravenous nutrition (86%), feeding tube (75%). 
The concordance rate between physicians and families was lowest for 
ventilator application (39%) and CPR (47%).
Decision-making regarding participation in research and high-cost 
options:
Controversy surrounds the enrollment of terminally ill patients in 
research studies. Many people argue that because of the nature of their 
illness these individuals are vulnerable, ill informed, can be coerced. 
However, data suggested that terminally ill individuals are well in-
formed about their cancer and well aware of most viable alternatives, 
from palliative care to hospice. Overall, it appears that concerns about 
the voluntariness and vulnerability of terminally ill patients are over-
stated and that their participation in clinical research at the end of life is 
a well informed decision. (5) In addition, high-cost options in treatment 
of lung cancer are causing difﬁculties in decision.
Decision-making regarding palliative care: 
Brundage et al. suggested that patients with advanced NSCLC should 
be offered more than one treatment option, and that a systematic pro-
cess for educating patients and for eliciting their preferences is desir-
able (6). Values held on issues like therapeutic decision-making and the 
withholding of life-sustaining treatments in terminal cancer patients are 
discordant between physicians and family members. In order to resolve 
controversies on the role of physicians in end-of-life decisions, the val-
ues of physicians, patients and of family members should be considered 
in the ﬁnal decision-making process.
In our study, 121 consecutive patients with advanced or terminal stage 
cancer were evaluated. The opinions of physicians, family member, and 
patients when family members permitted, using a questionnaire, were 
collected. About 30% of physicians and family members did not want 
to inform patients of the exact state of their diseases. When the opin-
ions of patients, family members, and physicians differed concerning 
life-sustaining treatment of terminal cancer patients, 78.3% of physi-
cians and 82.6% of patients believed that the ﬁnal decision should be 
made by the patient. However, only 47.9% of family members believed 
so. Moreover, in real practice, the treatment decision was made by 
patients in only 33% of cases, whereas 33% of cases were directed by 
a physician and 28% by family members. For ideal decision-making, 
almost all favored an informed decision, whilst 69.3% of physicians, 
64.8% of family members and 57.1% of patients favored a shared deci-
sion. More patients and family members than physicians regarded the 
role or responsibility of a physician as being of central importance.
Although informed shared decisions should be made concerning 
treatment-decisions in cancer patients, this is not usually reﬂected by 
practice. Medical decisions concerning the end-of-life care are very 
challenging to physicians, family members, and patients.
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